Your browser doesn't support javascript.
loading
Surgical Outcomes of Hugo™ RAS Robot-Assisted Partial Nephrectomy for Cystic Renal Masses: Technique and Initial Experience.
Prata, Francesco; Iannuzzi, Andrea; Tedesco, Francesco; Ragusa, Alberto; Civitella, Angelo; Pira, Matteo; Fantozzi, Marco; Sica, Leonilde; Scarpa, Roberto Mario; Papalia, Rocco.
Afiliação
  • Prata F; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Iannuzzi A; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Tedesco F; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Ragusa A; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Civitella A; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Pira M; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Fantozzi M; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Sica L; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Scarpa RM; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Papalia R; Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
J Clin Med ; 13(12)2024 Jun 19.
Article em En | MEDLINE | ID: mdl-38930124
ABSTRACT

Background:

The Hugo™ Robot-Assisted Surgery (RAS) system is a new cutting-edge robotic platform designed for clinical applications. Nevertheless, its application for cystic renal tumors has not yet been thoroughly investigated. In this context, we present an initial series of Robot-Assisted Partial Nephrectomy (RAPN) procedures carried out using the Hugo™ RAS system for cystic renal masses.

Methods:

Between October 2022 and January 2024, twenty-seven RAPN procedures for renal tumors were performed at Fondazione Policlinico Universitario Campus Bio-Medico. Our prospective board-approved dataset was queried for "cystic features" (n = 12). Perioperative data were collected. The eGFR was calculated according to the CKD-EPI formula. Post-operative complications were reported according to the Clavien-Dindo classification. Computed tomography (CT) scans for follow-up were performed according to the EAU guidelines. Trifecta was defined as the coexistence of negative surgical margin status, no Clavien-Dindo grade ≥ 3 complications, and eGFR decline ≤ 30%.

Results:

All the patients successfully underwent RAPN without the need for conversion or additional port placement. The median docking and console time were 5.5 (IQR, 4-6) and 79.5 min (IQR, 58-91 min), respectively. No intraoperative complications occurred, as well as clashes between instruments or with the bedside assistant. Two minor postoperative complications were recorded (Clavien-Dindo II). At discharge, serum creatinine and eGFR were comparable to preoperative values. Only one patient (8.4%) displayed positive surgical margins. The rate of trifecta achievement was 91.7%.

Conclusions:

RAPN for cystic renal masses using the novel Hugo™ RAS system can be safely and effectively performed. This robotic system provided satisfactory peri-operative outcomes, preserving renal function and displaying low postoperative complications and a high trifecta rate achievement.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article